Looking at pharmaceuticals beyond Covid-19

WE CAN be forgiven for thinking that pharmaceutical companies only care about finding a cure, a treatment, a test or even a vaccine for Covid-19 right now. It goes without saying that no expense should be spared to curb the spread of the deadly pathogen that has claimed over a million lives and infected more than 50 million people worldwide.

But there is more to the healthcare industry than just Covid-19. Another challenge - one that is less talked about, but no less economically crippling - is the ageing population. It has been described as the ticking time-bomb where one-fifth of the world's population is expected to be 60 or older by 2050.

Whilst Covid-19 justifiably grabs headlines, many healthcare companies are working tirelessly to address the healthcare issues of a rapidly-changing world demographic. There is even a name for it - epidemiological transition.